AbbVie’s upadacitinib received orphan drug designation from the European Medicines Agency (EMA) for the treatment of systemic sclerosis on 20 April 2026, with the designation registered under EU/3/26/3220 and the sponsor listed as AbbVie Deutschland GmbH & Co. KG.
In the EU, orphan drug designation provides a 10-year period of marketing exclusivity following product approval, along with incentives including protocol assistance from the EMA and direct access to the centralized authorization procedure.
Upadacitinib, marketed as Rinvoq, is a selective Janus Kinase 1 (JAK1) inhibitor developed entirely within AbbVie’s internal research programs following the company’s spin-off from Abbott Laboratories in 2013. The molecule was first approved by the US Food and Drug Administration (FDA) in August 2019 for rheumatoid arthritis and has since accumulated approvals across multiple inflammatory indications, including psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn’s disease, and ankylosing spondylitis. The systemic sclerosis designation represents an investigational expansion into a rare autoimmune connective tissue disease for which upadacitinib currently holds no marketing authorization in any jurisdiction.
No active systemic-sclerosis-specific clinical trial for upadacitinib was confirmed in the available evidence, representing a gap in the current public record. AbbVie has not disclosed a named Phase II or Phase III program in systemic sclerosis in the data available at the time of publication.
Within the JAK inhibitor class, upadacitinib’s selectivity profile for JAK1 over JAK2, JAK3, and TYK2 has been the basis for its differentiation from earlier, less selective agents such as tofacitinib, which inhibits JAK1 and JAK3 with comparable potency. In systemic sclerosis, where JAK-STAT signaling pathways are implicated in fibrotic and inflammatory disease mechanisms, this selectivity argument is being tested across the class, though clinical validation in this specific indication remains at an early stage across most programs. AbbVie’s move to seek orphan status in the EU positions Rinvoq alongside other JAK inhibitor assets being evaluated in the scleroderma space, though direct competitor trial data in systemic sclerosis was not available within the scope of the current evidence set.
The EMA orphan designation does not constitute authorization for use, and upadacitinib in systemic sclerosis will require full marketing authorization before it can be made available to patients in the EU.